Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Motor Development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    174 result(s) found for: Motor Development. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2012-003489-42 Sponsor Protocol Number: 31-12-294 Start Date*: 2013-03-12
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tics associated with Tourette’s Disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Ongoing) GB (Completed) ES (Prematurely Ended) IT (Completed) DE (Ongoing) SE (Completed) NL (Ongoing) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003488-23 Sponsor Protocol Number: 31-12-293 Start Date*: 2013-01-30
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tics associated with Tourette’s Disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) FI (Prematurely Ended) BE (Completed) SE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) DE (Prematurely Ended) NL (Not Authorised) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001315-44 Sponsor Protocol Number: TAK-935-18-002(OV935) Start Date*: 2022-05-24
    Sponsor Name:Takeda Development Center America, Inc.
    Full Title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
    Medical condition: Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073682 Dravet syndrome LLT
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    22.1 10010331 - Congenital, familial and genetic disorders 10083005 CDKL5 deficiency disorder PT
    23.0 10010331 - Congenital, familial and genetic disorders 10083952 Dup15q syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000468-83 Sponsor Protocol Number: 31-10-273 Start Date*: 2011-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003678-28 Sponsor Protocol Number: AVXS-101-CL-102 Start Date*: 2020-09-15
    Sponsor Name:AveXis, Inc.
    Full Title: Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting but Non- Ambulatory Patients with Spinal Muscular Atrophy
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000467-27 Sponsor Protocol Number: 31-10-272 Start Date*: 2011-11-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette's Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000469-11 Sponsor Protocol Number: 31-10-274 Start Date*: 2011-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) RO (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003453-18 Sponsor Protocol Number: RH-2015-200 Start Date*: 2015-11-25
    Sponsor Name:Rigshospitalet
    Full Title: A Randomized, Single-blinded, Cross-over Study investigating the Non-inferiority of Efficacy and Safety of HyQvia in comparison with Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropa...
    Medical condition: Multifocal Motor Neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064135 Polyneuropathy chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004424-15 Sponsor Protocol Number: NOE-TTS-211 Start Date*: Information not available in EudraCT
    Sponsor Name:Noema Pharma Australia Pty Ltd
    Full Title: An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult and adolescent male patients with To...
    Medical condition: Tourette Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10044127 Tourette's syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003370-35 Sponsor Protocol Number: MCT8-2019-2 Start Date*: Information not available in EudraCT
    Sponsor Name:Rare Thyroid Therapeutics International AB
    Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
    Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005044-86 Sponsor Protocol Number: flu2006 Start Date*: 2007-02-07
    Sponsor Name:Roessingh Research and Development
    Full Title: Influence of long-term administration of fluoxetine on cerebral threshold and muscle activity patterns in chronic stroke patients.
    Medical condition: The effect of fluoxetine on brain excitability and muscle activation will be measured in chronic stroke patients (> 6 months after stroke). As secondary measures, also brain activation, phase-synch...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003197-57 Sponsor Protocol Number: A0081181 Start Date*: 2012-11-09
    Sponsor Name:Pfizer Worldwide Research and Development
    Full Title: A MULTIPLE DOSE PHARMACOKINETIC OPEN-LABEL STUDY OF PREGABALIN (LYRICA) IN HEALTHY LACTATING WOMEN
    Medical condition: neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia neuropathic pain related to spinal cord injury (US), fibromyalgia (US, JP) treatment of central and periphe...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028005 Motor peripheral neuropathy LLT
    15.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    15.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    15.1 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    15.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    15.1 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002087-12 Sponsor Protocol Number: BN40703 Start Date*: 2018-12-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10079419 Spinal muscular atrophy pre-symptomatic LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005995-37 Sponsor Protocol Number: COAV101A12306 Start Date*: 2021-08-25
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase lllb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric pa...
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) PT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-005552-11 Sponsor Protocol Number: LTS12869 Start Date*: 2022-03-07
    Sponsor Name:Genzyme Corporation
    Full Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.
    Medical condition: Pompe disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000376-38 Sponsor Protocol Number: MT-1186-A03 Start Date*: 2021-03-22
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019891-54 Sponsor Protocol Number: WC2010-022 Start Date*: 2010-08-10
    Sponsor Name:VU University Medical Center
    Full Title: Effects of oral corticosteroids and DMSO on inflammatory signs and symptoms in Complex Regional Pain Syndrome type 1
    Medical condition: Complex regional pain syndrome type 1. This condition is a pain syndrome with unknown pathophysiology. Research shows that inflammation plays a role in the development and course of the disease. Ev...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005314-34 Sponsor Protocol Number: SRK-015-003 Start Date*: Information not available in EudraCT
    Sponsor Name:Scholar Rock, Inc.
    Full Title: Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or ...
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10041583 Spinal muscular atrophy, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) ES (Ongoing) NL (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001235-27 Sponsor Protocol Number: AVXS-101-CL-101 Start Date*: 2020-04-06
    Sponsor Name:AveXis, Inc.
    Full Title: Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA